Literature DB >> 2156619

Morphological and electrophysiological study of the effects of cisplatin and ORG.2766 on rat spinal ganglion neurons.

L J Müller1, R Gerritsen van der Hoop, C M Moorer-van Delft, W H Gispen, E W Roubos.   

Abstract

Eleven- to 12-wk-old rats were treated twice a week with cisplatin/saline or with cisplatin plus ORG.2766 during 12.5 wk. Cisplatin and ORG.2766 were administered at a final concentration of 0.04 mg/ml (i.p.) and 10 micrograms/ml (s.c.), respectively. Control animals were treated with saline. In this period the cisplatin-treated animals developed a peripheral neuropathy resulting in impairment of sensory functions. Estimates of the motor (MNCV) and sensory (SNCV) nerve conduction velocity were made after 0, 7.5, 10, and 12.5 wk. It appeared that the MNCV of the control, cisplatin-, and cisplatin plus ORG.2766-treated rats increased from 50 to 59 m/s. In contrast, the SNCV of the cisplatin-treated rats decreased significantly (P less than 0.001) from 63 to 56 m/s, whereas that of the control animals increased from 62 to 84 m/s. Rats which received cisplatin plus ORG.2766 showed an increase in SNCV up to control levels. After 12.5 wk the animals were perfused with a mixture of 1% paraformaldehyde and 1.25% glutaraldehyde in 0.05 M phosphate buffer. At the level of L5 and L6, 5 mm of spinal cord tissue and three dorsal root ganglia were removed and processed for electron microscopy. With the point-counting method the volume fraction (v/v) of somata and myelin in spinal ganglia was estimated. No significant change in the volume fraction of somata of the control (0.42), cisplatin (0.33)-, and cisplatin plus ORG.2766 (0.39)-treated rats was found. The same held true for the volume fraction of myelin of the control (0.53), cisplatin (0.59)-, and cisplatin plus ORG.2766 (0.58)-treated rats. In addition, the number of lysosomes per 100 microns 2 was estimated in spinal ganglion neurons and in spinal cord motor neurons of a total of 120 randomly chosen neurons. It was found that the number of lysosomes in the spinal ganglion neurons of the control animals was lower (10 per 100 microns 2) than in cisplatin-treated (30 per 100 microns 2) and in cisplatin plus ORG.2766-treated rats (28 per 100 microns 2) (P less than 0.05). No difference was observed in the number of lysosomes between cisplatin- and cisplatin plus ORG.2766-treated rats. The number of lysosomes in spinal cord tissue of cisplatin-treated rats (2.4 per 100 microns 2) did not differ from controls (0.1 per 100 microns 2) and from cisplatin plus ORG.2766-treated rats (0.8 per 100 microns 2).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156619

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration.

Authors:  G Tredici; S Tredici; D Fabbrica; C Minoia; G Cavaletti
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

2.  Depletion of Mitofusin-2 Causes Mitochondrial Damage in Cisplatin-Induced Neuropathy.

Authors:  Ilja Bobylev; Abhijeet R Joshi; Mohammed Barham; Wolfram F Neiss; Helmar C Lehmann
Journal:  Mol Neurobiol       Date:  2017-01-21       Impact factor: 5.590

3.  Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue.

Authors:  Virginia Ip; Johnson J Liu; Julian F B Mercer; Mark J McKeage
Journal:  Mol Pain       Date:  2010-09-13       Impact factor: 3.395

4.  Effects of cisplatin and ORG.2766 in chick embryonic brain cell cultures.

Authors:  A Bruinink; F Birchler
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

5.  Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study.

Authors:  A Olivi; M Gilbert; K L Duncan; B Corden; D Lenartz; H Brem
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766.

Authors:  F P Hamers; C Pette; B Bravenboer; C J Vecht; J P Neijt; W H Gispen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 7.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats.

Authors:  G Cavaletti; G Tredici; P Marmiroli; M G Petruccioli; I Barajon; D Fabbrica
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

9.  Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity.

Authors:  S M F Jamieson; J Liu; T Hsu; B C Baguley; M J McKeage
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  Long-term neurotoxicity of chemotherapy in adolescents and young adults treated for bone and soft tissue sarcomas.

Authors:  H M Earl; S Connolly; C Latoufis; K Eagle; C M Ash; C Fowler; R L Souhami
Journal:  Sarcoma       Date:  1998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.